Lung Transplantation in Idiopathic Pulmonary Fibrosis Patients in the European MultiPartner IPF Registry: Challenges for Health Equity

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F25%3A10001403" target="_blank" >RIV/00064190:_____/25:10001403 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/25:00143160

Výsledek na webu

<a href="https://doi.org/10.3390/biomedicines13112684" target="_blank" >https://doi.org/10.3390/biomedicines13112684</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3390/biomedicines13112684" target="_blank" >10.3390/biomedicines13112684</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Lung Transplantation in Idiopathic Pulmonary Fibrosis Patients in the European MultiPartner IPF Registry: Challenges for Health Equity

Popis výsledku v původním jazyce

&lt;bold&gt;Background:&lt;/bold&gt; Despite advancements in pharmacological therapy, lung transplantation (LuTX) remains the only life-prolonging treatment in end-stage idiopathic pulmonary fibrosis (IPF). However, real-world referral patterns in Central and Eastern European (CEE) countries remain poorly characterized. We aimed to comprehensively review factors influencing referral and identify systemic barriers to LuTX access. &lt;bold&gt;Methods:&lt;/bold&gt; Baseline characteristics of IPF patients potentially eligible for LuTX, enrolled in the European MultiPartner IPF Registry between 2012 and 2022 (n = 1256), were retrospectively analyzed. LuTX (n = 94) and potentially eligible but not transplanted (n = 1162) subgroups were compared. National experts also completed a questionnaire assessing transplant referral and listing practices across different healthcare systems. &lt;bold&gt;Results:&lt;/bold&gt; Only 7.5% of potentially eligible subjects were transplanted, revealing substantial geographic disparities, with Israel having the highest rates (43.1%), followed by Austria (9.5%), Hungary (7.8%), and the Czech Republic (4.6%). LuTX patients were younger (60.2 +/- 7.4 vs. 62.6 +/- 6.2 years, p &lt; 0.001), had worse lung function (FVC 60 +/- 15 vs. 74 +/- 21% predicted; p &lt; 0.001, TLCO 41 +/- 15 vs. 49 +/- 19% predicted; p &lt; 0.001), and were more likely to receive antifibrotic and oxygen therapies. The most frequent reasons for exclusion from referral/listing were age &gt; 70 years and concomitant heart/renal failure. &lt;bold&gt;Conclusions:&lt;/bold&gt; This first comprehensive CEE analysis demonstrates low IPF transplant rates with high inter-country variability. Patients presenting early with functionally advanced disease are more likely transplanted, while advanced age remains the primary exclusion factor, highlighting critical access gaps potentially contributing to regional outcome differences.

Název v anglickém jazyce

Lung Transplantation in Idiopathic Pulmonary Fibrosis Patients in the European MultiPartner IPF Registry: Challenges for Health Equity

Popis výsledku anglicky

&lt;bold&gt;Background:&lt;/bold&gt; Despite advancements in pharmacological therapy, lung transplantation (LuTX) remains the only life-prolonging treatment in end-stage idiopathic pulmonary fibrosis (IPF). However, real-world referral patterns in Central and Eastern European (CEE) countries remain poorly characterized. We aimed to comprehensively review factors influencing referral and identify systemic barriers to LuTX access. &lt;bold&gt;Methods:&lt;/bold&gt; Baseline characteristics of IPF patients potentially eligible for LuTX, enrolled in the European MultiPartner IPF Registry between 2012 and 2022 (n = 1256), were retrospectively analyzed. LuTX (n = 94) and potentially eligible but not transplanted (n = 1162) subgroups were compared. National experts also completed a questionnaire assessing transplant referral and listing practices across different healthcare systems. &lt;bold&gt;Results:&lt;/bold&gt; Only 7.5% of potentially eligible subjects were transplanted, revealing substantial geographic disparities, with Israel having the highest rates (43.1%), followed by Austria (9.5%), Hungary (7.8%), and the Czech Republic (4.6%). LuTX patients were younger (60.2 +/- 7.4 vs. 62.6 +/- 6.2 years, p &lt; 0.001), had worse lung function (FVC 60 +/- 15 vs. 74 +/- 21% predicted; p &lt; 0.001, TLCO 41 +/- 15 vs. 49 +/- 19% predicted; p &lt; 0.001), and were more likely to receive antifibrotic and oxygen therapies. The most frequent reasons for exclusion from referral/listing were age &gt; 70 years and concomitant heart/renal failure. &lt;bold&gt;Conclusions:&lt;/bold&gt; This first comprehensive CEE analysis demonstrates low IPF transplant rates with high inter-country variability. Patients presenting early with functionally advanced disease are more likely transplanted, while advanced age remains the primary exclusion factor, highlighting critical access gaps potentially contributing to regional outcome differences.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30203 - Respiratory systems

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Biomedicines

ISSN

2227-9059

e-ISSN

2227-9059

Svazek periodika

13

Číslo periodika v rámci svazku

11

Stát vydavatele periodika

CH - Švýcarská konfederace

Počet stran výsledku

16

Strana od-do

nestránkováno

Kód UT WoS článku

001625770000001

EID výsledku v databázi Scopus

2-s2.0-105023068947